BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
BCRXBioCryst Pharmaceuticals(BCRX) Zacks Investment Research·2024-02-26 22:11

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of 0.28pershareversustheZacksConsensusEstimateofalossof0.28 per share versus the Zacks Consensus Estimate of a loss of 0.24. This compares to loss of 0.38pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof−16.670.38 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -16.67%. A quarter ago, it was expected that this drugmaker would post a loss of 0.25 per share when it actually produced a loss of $0.19, delivering a surprise of 24%. Over the last four quarters, the company h ...